ArticleFrontiers in immunology2024

A single-center, retrospective study-spring-evaluating the efficacy and safety of recombinant human vascular endothelial inhibitor combined with anti-PD-1 in elderly patients aged 80 and above with NSCLC.

Tian Xing et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.